Quest Diagnostics (DGX) Stock Price, News & Analysis

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Quest Diagnostics in the last year. There are currently 9 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DGX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DGX, but not buy additional shares or sell existing shares.
View DGX analyst ratings or view top-rated stocks.

11 equities research analysts have issued 1-year price targets for Quest Diagnostics' shares. Their DGX share price targets range from $130.00 to $165.00. On average, they predict the company's share price to reach $146.75 in the next year. This suggests a possible upside of 6.4% from the stock's current price.
View analysts price targets for DGX or view top-rated stocks among Wall Street analysts.

Quest Diagnostics' stock was trading at $156.44 at the beginning of 2023. Since then, DGX shares have decreased by 11.9% and is now trading at $137.88.
View the best growth stocks for 2023 here.

Quest Diagnostics saw a increase in short interest during the month of December. As of December 15th, there was short interest totaling 2,550,000 shares, an increase of 12.3% from the November 30th total of 2,270,000 shares. Based on an average daily trading volume, of 934,500 shares, the short-interest ratio is presently 2.7 days. Approximately 2.3% of the company's stock are short sold.
View Quest Diagnostics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 1st 2024.
View our DGX earnings forecast.

Quest Diagnostics Incorporated (NYSE:DGX) announced its quarterly earnings results on Tuesday, October, 24th. The medical research company reported $2.22 earnings per share for the quarter, topping the consensus estimate of $2.19 by $0.03. The medical research company earned $2.30 billion during the quarter, compared to the consensus estimate of $2.27 billion. Quest Diagnostics had a net margin of 8.21% and a trailing twelve-month return on equity of 15.80%. The firm's revenue for the quarter was down 7.7% compared to the same quarter last year. During the same quarter last year, the business posted $2.36 EPS.
Read the conference call transcript.

Quest Diagnostics declared a quarterly dividend on Monday, November 13th. Stockholders of record on Wednesday, January 17th will be paid a dividend of $0.71 per share on Wednesday, January 31st. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.06%. The ex-dividend date is Tuesday, January 16th.
Read our dividend analysis for DGX.

Quest Diagnostics (NYSE:DGX) pays an annual dividend of $2.84 per share and currently has a dividend yield of 2.06%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 42.64%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, DGX will have a dividend payout ratio of 31.56% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for DGX.

ETFs with the largest weight of Quest Diagnostics (NYSE:DGX) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM), AAM Bahl & Gaynor Small/Mid Cap Income Growth ETF (SMIG), BTD Capital Fund (DIP), iShares U.S. Healthcare Providers ETF (IHF), American Century Focused Large Cap Value ETF (FLV), Davis Select U.S. Equity ETF (DUSA), SPDR S&P Health Care Services ETF (XHS) and Freedom Day Dividend ETF (MBOX).

Quest Diagnostics announced that its board has approved a stock repurchase plan on Thursday, February 2nd 2023, which permits the company to buyback $1,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to buy up to 6% of its shares through open market purchases. Shares buyback plans are generally a sign that the company's management believes its stock is undervalued.

Quest Diagnostics issued an update on its FY23 earnings guidance on Tuesday, October, 24th. The company provided earnings per share (EPS) guidance of $8.65-8.75 for the period, compared to the consensus EPS estimate of $8.71. The company issued revenue guidance of $9.19-9.24 billion, compared to the consensus revenue estimate of $9.18 billion.

1,053 employees have rated Quest Diagnostics Chief Executive Officer Steve Rusckowski on Glassdoor.com. Steve Rusckowski has an approval rating of 78% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Quest Diagnostics investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Johnson & Johnson (JNJ), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE), Abbott Laboratories (ABT), NVIDIA (NVDA), Intel (INTC) and Cisco Systems (CSCO).

Shares of DGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.